微创心通医疗科技有限公司(“微创心通”，股份代号：2160)发布公告称，股份合并的全部条件已于2026年2月24日(星期二)达成，相关合并于当日正式生效。
微创心通此前于2026年1月27日刊发通函，并于2026年1月30日发布补充公告，对股份合并事宜进行了说明和修订后的预期时间表。公司在2026年2月11日召开的股东特别大会上对股份合并进行了投票表决，随后确认股份合并条件已全部满足。
根据公告，股份合并的买卖安排、免费换领股票及合并股份碎股对盘服务的更多详情，请参考公司通函及相关公告。公告显示，所有条款和时间安排均以公司公布的经修订预期时间表为准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.